drugset / Trial / NCT00534079

Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

NCT00534079 ↗

Phase 3 Completed 23 enrolled University of Jena
RandomizedCrossoverQuadruple-blindTreatment

Summary

Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.

Timeline

Start
2007-09
Primary completion
2009-02
Completion
2009-02

Outcome

Met primary endpoint

paper Primary nasal symptoms improved significantly with dornase alfa compared with no treatment, while small improvements with isotonic saline did not reach significance. PMID 24594542 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject dornase alfa Protein / enzyme biologic 2.5 ml Inhaled